Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Novacare (NOV) breaking out... -- Ignore unavailable to you. Want to Upgrade?

To: JB Cocallas who wrote (228)	2/10/1998 12:57:00 PM
From: Todd D. Wiener	Read Replies (1) \| Respond to of 420

Jim- Although it is a possibility, it doesn't make sense that NCES should be holding back NOV. Then again, the market seldom makes sense. The simple fact that NCES went public makes NOV stock more valuable. Alas, it might require another quarterly report before these stocks take off. Regardless, my 2 year price target is $25 for NOV and $20 for NCES. NCES offers a better return from current prices, but it's also slightly riskier. For every $3 NCES rises in price, NOV should increase in price by $1, based on the value of NCES stock to NOV. So if NCES were to climb to $20, NOV should trade at $17, if only because of its ownership in NCES. Todd